CN107848973A - S‑(‑)‑1‑丙基‑2’,6’‑二甲苯胺甲酰基哌啶晶体及其缓释制剂 - Google Patents

S‑(‑)‑1‑丙基‑2’,6’‑二甲苯胺甲酰基哌啶晶体及其缓释制剂 Download PDF

Info

Publication number
CN107848973A
CN107848973A CN201680037141.8A CN201680037141A CN107848973A CN 107848973 A CN107848973 A CN 107848973A CN 201680037141 A CN201680037141 A CN 201680037141A CN 107848973 A CN107848973 A CN 107848973A
Authority
CN
China
Prior art keywords
dimethylaniline
propyl
preparation
ropivacaine
sterile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680037141.8A
Other languages
English (en)
Inventor
叶强
严庞科
冯卫
万华
张轩邈
汪东海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of CN107848973A publication Critical patent/CN107848973A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

提供一种长效酰胺类局麻药S‑(‑)‑1‑丙基‑2',6'‑二甲苯胺甲酰基哌啶的晶体、其缓释制剂和它们的制备方法，该晶体制成的制剂与现有的盐酸盐制剂相比，具有特别良好的持续缓慢释放药物并保持有效血药浓度的属性，显示出优异的长效局部镇痛效果。

Description

PCT国内申请，说明书已公开。

Claims (42)

  1. PCT国内申请，权利要求书已公开。
CN201680037141.8A 2015-09-01 2016-09-01 S‑(‑)‑1‑丙基‑2’,6’‑二甲苯胺甲酰基哌啶晶体及其缓释制剂 Pending CN107848973A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510551415 2015-09-01
CN2015105514152 2015-09-01
PCT/CN2016/097784 WO2017036408A1 (zh) 2015-09-01 2016-09-01 S-(-)-1-丙基-2',6'-二甲苯胺甲酰基哌啶晶体及其缓释制剂

Publications (1)

Publication Number Publication Date
CN107848973A true CN107848973A (zh) 2018-03-27

Family

ID=58186725

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680037141.8A Pending CN107848973A (zh) 2015-09-01 2016-09-01 S‑(‑)‑1‑丙基‑2’,6’‑二甲苯胺甲酰基哌啶晶体及其缓释制剂

Country Status (2)

Country Link
CN (1) CN107848973A (zh)
WO (1) WO2017036408A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114522141A (zh) * 2021-04-08 2022-05-24 浙江仙琚萃泽医药科技有限公司 一种罗哌卡因混悬注射液及其制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017009861A1 (en) * 2015-07-13 2017-01-19 Neon Laboratories Limited Hyperbaric injection solution of ropivacaine hydrochloride and process for preparation thereof
CN109996787B (zh) * 2017-03-27 2022-07-05 合肥合源药业有限公司 难溶性复合物或其溶剂合物、药物组合物及其应用
CN109134352A (zh) * 2018-09-21 2019-01-04 合肥锐思生物医药有限公司 一种制备难溶性复合物或其溶剂合物的方法
CN110934868A (zh) * 2018-09-21 2020-03-31 合肥合源药业有限公司 难溶性复合物、药物组合物及其应用
CN110935024B (zh) * 2018-09-21 2023-08-08 合肥合源药业有限公司 长效组合物
CN114522145A (zh) * 2021-11-02 2022-05-24 浙江仙琚萃泽医药科技有限公司 制备罗哌卡因粉末制剂的方法以及由此获得的罗哌卡因粉末制剂
CN114504552A (zh) * 2021-11-02 2022-05-17 浙江仙琚萃泽医药科技有限公司 制备罗哌卡因混悬注射液和粉末制剂的方法以及由此获得的罗哌卡因混悬注射液和粉末制剂

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276654A1 (en) * 2005-06-06 2006-12-07 Navinta Llc Process of making optically pure L-pipecolic acid and process of making anesthetics and intermediates therefrom
WO2009044404A1 (en) * 2007-10-01 2009-04-09 Ramniwas Goel Process for the preparation of (s)-ropivacaine hydrochloride monohydrate
WO2009089841A1 (en) * 2008-01-15 2009-07-23 Pharmathen S.A. Process for the preparation of (s)-1-alkyl-2',6'-pipecoloxylidide compound
CN103086954A (zh) * 2013-02-04 2013-05-08 山东省医药工业研究所 一种制备罗哌卡因的方法
CN103142458A (zh) * 2013-01-22 2013-06-12 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
CN103524400A (zh) * 2013-10-24 2014-01-22 宜昌人福药业有限责任公司 一种n-(2’,6’-二甲苯基)-2-哌啶甲酰胺类局麻药的纯化方法
CN104146972A (zh) * 2014-08-27 2014-11-19 王丽萍 罗哌卡因纳米粒及其制备方法以及其效果的优化实验方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276654A1 (en) * 2005-06-06 2006-12-07 Navinta Llc Process of making optically pure L-pipecolic acid and process of making anesthetics and intermediates therefrom
WO2009044404A1 (en) * 2007-10-01 2009-04-09 Ramniwas Goel Process for the preparation of (s)-ropivacaine hydrochloride monohydrate
WO2009089841A1 (en) * 2008-01-15 2009-07-23 Pharmathen S.A. Process for the preparation of (s)-1-alkyl-2',6'-pipecoloxylidide compound
CN103142458A (zh) * 2013-01-22 2013-06-12 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
CN103086954A (zh) * 2013-02-04 2013-05-08 山东省医药工业研究所 一种制备罗哌卡因的方法
CN103524400A (zh) * 2013-10-24 2014-01-22 宜昌人福药业有限责任公司 一种n-(2’,6’-二甲苯基)-2-哌啶甲酰胺类局麻药的纯化方法
CN104146972A (zh) * 2014-08-27 2014-11-19 王丽萍 罗哌卡因纳米粒及其制备方法以及其效果的优化实验方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114522141A (zh) * 2021-04-08 2022-05-24 浙江仙琚萃泽医药科技有限公司 一种罗哌卡因混悬注射液及其制备方法

Also Published As

Publication number Publication date
WO2017036408A1 (zh) 2017-03-09

Similar Documents

Publication Publication Date Title
CN107848973A (zh) S‑(‑)‑1‑丙基‑2’,6’‑二甲苯胺甲酰基哌啶晶体及其缓释制剂
JP5221343B2 (ja) 担体
KR101492361B1 (ko) 바람직하게 ｓａｉｂ와 같은 당 에스테르를 포함하는 지속적인 국소 마취제 조성물
EP3505161B1 (en) Sublingual pharmaceutical composition of edaravone and (+)-2-borneol
CN104427976B (zh) 疏水的活性成分的储库制剂及其制备方法
EP2523653B1 (en) Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
CN110420211A (zh) 治疗炎症、自身免疫性疾病和疼痛的方法
WO2007015453A1 (ja) ピリドンカルボン酸誘導体を含有するローション剤
US20240108603A1 (en) Material and method for treating cancer
EP2590620B1 (en) Stable aqueous formulations comprising poorly water soluble active ingredients
CN112823787B (zh) 一种含有美洛昔康的注射液及其制备方法
CN110327336B (zh) 昔萘酸甲哌卡因及其长效缓释制剂
CN110101660B (zh) 一种包含有地佐辛与利卡多因的复方药物缓释制剂及其制备方法
CN116617160A (zh) 水性混悬液及制备方法、冻干粉及应用、脂肪消减注射剂
BR112020024590A2 (pt) Formulações de tegavivint e compostos relacionados
WO2022193975A1 (zh) 供注射用罗哌卡因长效溶液制剂及其制备方法
EP4052694A1 (en) Eye drop composition for preventing or treating eye disease
US20160022584A1 (en) Pharmaceutical compositions of goserelin sustained release microspheres
KR101130754B1 (ko) 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물
US20220409560A1 (en) Pharmaceutical Compositions, Formulations And Methods For The Treatment Of Retinoblastoma
CN105232617A (zh) 黄芪总苷在制备预防或治疗微波辐射致神经细胞损伤药物中的用途、药物组合物及食品
KR20210019402A (ko) 주사용 조성물
CN116211799B (zh) 一种局麻药复合物混悬剂
US20220218608A1 (en) Injectable polymer nanoparticle compositions of antithrombotic agents and methods thereof
CN116099007A (zh) 一种局麻药与生物碱的帕莫酸盐缓释组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180327